



Available online on 15.9.2020 at <http://ujpr.org>
Universal Journal of Pharmaceutical Research
An International Peer Reviewed Journal

Open access to Pharmaceutical research
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial Share Alike 4.0 License which permits unrestricted non commercial use, provided the original work is properly cited



Open Access

Volume 5, Issue 4, 2020

REVIEW ARTICLE

EUCALYPTUS ESSENTIAL OIL; AN OFF-LABEL USE TO PROTECT THE WORLD FROM COVID-19 PANDEMIC: REVIEW-BASED HYPOTHESES

Hatem Sameir Abbass 

Department of Pharmacognosy, Faculty of Pharmacy, Al-Azhar University (Boys), Cairo 11371-Egypt.
Department of Pharmacognosy, Faculty of Pharmacy, Sinai University, Kantara 41636-Egypt.

ABSTRACT

Objective: Severe acute respiratory syndrome Coronavirus 2 causes both health and economic crises and up till now no drug or vaccine has yet been approved. There is an increased demand to explore other complementary methods to protect the world. Eucalyptus essential oil; a popular off-label drug used to relieve nasal congestion via inhalation with promising effects on the upper respiratory diseases including viral infections.

Methods: In order to provide review-based hypotheses demonstrating eucalyptus essential oil beneficial role; several published studies were retrieved from different databases and websites till June 2020. The retrieved data declared the antiviral potentials against viruses of same subgenus or with same pattern and the beneficial effects on respiratory system, immunity and overall health improvement, along with declaring the application methods and safety.

Results: Off-label use of Eucalyptus essential oil by inhaling 12drops /150mL or 1.5% v/v solution boiling water may relief COVID-19 mild and moderate symptoms as pain, cough, respiratory inflammation, cytokine storm and dyspnea.

Conclusions: Experimental and clinical data proved that inhalation of eucalyptus essential oil may provide the ability to reduce COVID-19 patients symptoms and morbidity risk factors and may play a role as a preventative technique complementary to WHO guidance for beating COVID-19 virulence and transmission spread.

Keywords: Cineole, COVID-19, essential oil, eucalyptus oil, inhalation.

Article Info: Received 28 June 2020; Revised 20 July; Accepted 10 August, Available online 15 September 2020



Cite this article-

Abbass HS. Eucalyptus essential oil; an off-label use to protect the world from COVID-19 pandemic: review-based hypotheses. Universal Journal of Pharmaceutical Research 2020; 5(4):61-64.

DOI: <https://doi.org/10.22270/ujpr.v5i4.440>

Address for Correspondence:

Dr. Hatem Sameir Abbass, Department of Pharmacognosy, Faculty of Pharmacy, Al-Azhar University (Boys), Cairo 11371-Egypt. Department of Pharmacognosy, Faculty of Pharmacy, Sinai University, Kantara 41636-Egypt., Tel: +00201092900910, E-mail: hsam8406@azhar.edu.eg

INTRODUCTION

Corona virus disease 2019 (COVID-19) is a global pandemic of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It first appeared in Wuhan, Hubei, China and then spreads all over the world through respiratory droplets, contact and the faecal-oral route¹. World Health Organization (WHO) listed COVID-19 as a public health emergency of international concern due to its rapid and highly infectious pattern. The last WHO situation report-134 up to date June 2, 2020 has confirmed a total number of infected peoples to be 6194533 from which 376320 were died². The nowadays pandemic is characterized by intensity variation between countries, misleading indication of case fatality rate and unclear data about the virus and its virulence. The absence of vaccines and treatments encouraged the control strategies role and non-pharmacological measurements for communities³. Several intervention therapeutic strategies were reported as an alternative approach to control the

COVID-19 pandemic. From these strategies the inhalation of Eucalyptus essential oil (EEO) which reported in several publications in addition to folkloric traditional use in some countries during the few last days⁴⁻⁹. No clinical trial, in vivo or in vitro studies demonstrate the EEO activity against COVID-19; but several review-based expected potentials as antiviral, co-infection control, symptoms relief or just a safe hygienic lifestyle. Today many companies have advertised to EEO as a product for prevention or treatment of COVID-19¹⁰; but, US Food and Drug Administration (FDA) had sent a warning letters to such companies¹¹. In this work I will declare both facts and problems of EEO use in controlling COVID-19 pandemic.

METHODS

Literature search was performed using different databases as; Science Direct, Google Scholar, Web of Science, PubMed, ClinicalTrials.gov and Scopus using

main key word “Eucalyptus” in addition to “COVID-19, COPD, Antiviral, Anti-inflammatory, Immune modulation, Antimicrobial, clinical trials, FDA, Monograph, Inhalation and Potential”.

DISCUSSION

Off-label use of EEO: EEO widely used as Over The Counter (OTC) drug in a single or combined form for relieving nasal congestion via inhaling a few drops either on a handkerchief or in a bowl of hot water¹². Vapor inhalation of EEO relief symptoms of bronchitis, asthma, and chronic obstructive pulmonary disease (COPD) which are the risk factors in COVID-19 patients¹³. Traditional use of EEO for relief of cough associated with cold are accepted without the supervision of a medical practitioner via inhalation and as a bath additive and had been described for a long time¹⁴. 1,8-Cineole the major constituent of EEO (80-95%) is well tolerated in inhalation administrations and is registered as a licensed medicinal product which available for airways inflammation for many years¹⁵. As well Vicks VapoRub® vapors inhalation which containing eucalyptus, camphor and menthol acting on cold receptors in the nose are a common used off-label drug. The German Standard zulassung, the Pharmacopée Française and the WHO monograph 2002 had reported the use of EEO for the treatment of respiratory tract disorders, bronchial catarrh and stomach pain¹⁴. The Martindale reported that EEO effective as an inhalant, often in combination with other volatile oils for catarrh and coughs in a lot of preparations¹⁶. EEO is approved by the FDA for food use (EAFUS -Everything Added to Food in the United States- list No 2081) [FDA 2013] and as OTC (Over the counter) drug in cough/cold monograph sub-categories nasal decongestant (mouthwash or lozenge), antitussive and expectorant and in external analgesic monograph sub-categories counter irritant, fever blister/cold sore and poison ivy/oak/sumac and in skin protectant monograph sub-categories astringent and poison (ivy/oak/sumac)¹⁷.

COPD control by EEO: COPD is associated with increased risk of morbidity in COVID-19 patients¹⁸. Pretreatment with EEO markedly reduced the production TNF- α and IL- β proinflammatory cytokines, superoxide dismutase (SOD) activity and malondialdehyde (MDA) level which indicates that EEO might have its potential in COPD treatment¹⁹. The anti-inflammatory effect EEO to reduce cytokine release was confirmed also in ex-vivo cultured and stimulated alveolar macrophages from patients with (COPD)²⁰. Few weeks (1-8) therapy with 1,8-Cineole reduces exacerbations, dyspnea and specific airway resistance in patients with COPD and improves lung function parameters and health status by intervening in the mucus membrane pathophysiology of airway inflammation¹⁴.

Antiviral activity of EEO: The antiviral activity of EEO was confirmed against an enveloped viruses (similar to COVID-19); mumps virus obtained from patients with respiratory tract infection²¹, herpes simplex virus before or during host cell adsorption²², H₁N₁ influenza virus²³ and inhibits avian influenza virus

H₁N₉ in aerosol, vapor and if being captured on a fiber coating materials⁹. The inhibitory mechanism of EEO is based on the inactivation of hemagglutinin protein of the virus in its vapor phase⁹. As well, two preprint articles by (Sharma *et al.*) demonstrated that eucalyptol (1,8 cineole) and Jensenone from EEO represent potential COVID-19 main viral proteinase (M-pro/3CLpro) inhibitory effect by molecular docking studies. Inhaling concentrated EEO vapors for 30 minutes followed by periodical inhaling vapor mixture of EEO and tea tree oil (TTO) (50:50) with 30-120 minutes intervals; reduces the risk of infection with SARS-CoV which is a highly pathogenic coronavirus^{23,24}.

Co-infection control activity of EEO: The antibacterial potentials of EEO was confirmed by activity against respiratory infecting bacteria; *Haemophilus influenzae*, *H. parainfluenzae*, *Stenotrophomonas maltophilia* and *Streptococcus pneumoniae*²¹ and by inhalation prophylactic use against colds, tuberculosis, flus and opportunistic infections of the human respiratory system²⁴. In hospitals EEO used for controlling multidrug-resistant bacteria²⁵, reduce endotracheal tube biofilm microbial contamination during ventilation process²⁶ and showed antifungal potential against intensive care units (ICU) isolated yeast^{24,27}. EEO fumes inhalation affords bactericidal components killing infections in the nasal passages, sinuses, bronchial tubes and lungs²⁴.

Anti-inflammatory and Immune modulation potentials of EEO: Dexamethasone today is the first and only drug that has made a significant difference to patient mortality for COVID-19 due to its anti-inflammatory and immune modulation effects. Surprisingly EEO can implement the innate cell-mediated immune response and anti-inflammatory properties^{28,29}. COVID-19 hospitalized patients developed at latter phase a syndrome known as cytokine storm or hyperinflammatory syndrome due to immune overactivation that increases the acute respiratory distress and can lead to death³⁰. Pretreatment with EEO markedly reduced the production of proinflammatory cytokines which indicates that EEO might have its potential to stop cytokine storm¹⁹. As well suppression of human lung macrophages inflammatory responses by EEO and its constituent 1,8-cineole was reported³¹.

Other activities of EEO: EEO decreasing patient's pain³², cough treatment³³, aid in the recovery from certain respiratory diseases²⁴, air freshener, fumigating agent³⁴ and effective in cleaning mixtures for degreasing, deodorizing and disinfection^{33,35}.

Dose and safety of EEO: The WHO monograph EEO reported doses were 12drops /150mL or 1.5% v/v solution boiling water for inhalation three times daily^{36,37}. The oral LD₅₀ in rats (2.5g/kg)³⁸. A toxicological study influenced the use of EEO with certain concentration less than (233.44 mg/kg) to avoid serious metabolic and cellular damage³⁹. As well, EEO also may cause irritation to the skin, toxic effects especially in children and adverse effects as slurred speech, ataxia, muscle weakness progressing to unconsciousness and seizures if used in high

concentration⁴⁰⁻⁴². Because of EEO strong odor, an accidental poisoning is not common, as intoxication occurs only via oral consumption of 4-5ml EEO⁵. There is no danger of accumulating inhaled essential oils in the body even with repeated inhalation as the concentration of inhaled EO decreases to half its original value within 30-40 minutes²⁴. However the oils liquid phase are generally irritant and possibly toxic for nasopharyngeal and lung epithelial cells, the vapor phase of the same oils might be useful as inhalers for respiratory infections in low concentrations¹⁵. Studies on 1,8-cineole confirmed that it is well absorbed from breathing air. Upon inhalation of 2 ml 1,8-cineole 99% for 20 min. the blood serum concentration was increasing in a linear way with distribution half-life 2-13 min. and elimination half-life 31-281 min.

Clinical trials of EEO on human volunteers: The effect of 0.25ml EEO inhalation for 10 minutes on cardiovascular responses using a disposable face mask was reported in (ClinicalTrials.gov Identifier: NCT02656004) and smelling of pure EEO in vial for training of the olfactory nerve for improving smell sense after radiation therapy also reported in (ClinicalTrials.gov Identifier: NCT03049358). EEO 100% concentration was confirmed as a safe method of protection from mosquito bites on human volunteers skin in indoor conditions³⁴. Inhalation of EEO was effective in reducing blood pressure and pain after total knee replacement³². Another clinical study had concluded that the treatment with 1,8-cineole of patients with acute non-purulent rhinosinusitis was effective and safe with only mild side effects and can avoid antibiotic treatment⁴³. Another study had concluded that acute rhinosinusitis can be managed by treatment with 1,8-cineole and confirmed its safety and significant benefit for bronchitis⁴⁴.

Precautions for using EEO: EEO should not be used during pregnancy or lactation as there is no information available on inhalation of EEO or its main constituent 1,8-cineole for pregnant women and 1,8-cineole has been reported to penetrate the rodents placenta. EEO should not be used for babies and very young children less than 12 years as the risk of reflex spasm is expected.

CONCLUSION

Off-label use of EEO as an inhaler via inhalation vaporizers, diffusers or as a fragrance in cleaning mixtures should be announced as a concomitant safe hygienic lifestyle to hand washing, face mask wearing and social distancing. The use of EEO for COVID-19 patients will reduce muscle and stomach pain, cough and dyspnea which are the common symptoms, and protect patients from co-infection susceptibility and decrease chance of hyper inflammatory syndrome and COPD associated risk morbidity. Researchers should start the clinical trials and in vivo studies on EEO safety and efficacy as soon as possible to confirm or reject its antiviral potentials against COVID-19 to evaluate the possibility of its use for treatment and/or prevention. Community pharmacies and essential oil manufactories should sell EEO just as an off-label drug

not as treatment or preventative protocol for COVID-19 pandemic.

CONFLICT OF INTEREST

The author declares no conflict of interest.

REFERENCES

1. Yeo C, Kaushal S, Yeo D. Enteric involvement of corona viruses: is faecal-oral transmission of SARS-CoV-2 possible? The lancet Gastroenterology & hepatology. 2020; 5(4):335-337. [https://doi.org/10.1016/S2468-1253\(20\)30048-0](https://doi.org/10.1016/S2468-1253(20)30048-0)
2. Organization WH. Corona virus disease (COVID-19). Situation Report 134. 2 June 2020.
3. Mansuri FM. Situation analysis and an insight into assessment of pandemic COVID-19. J Taibah University Medical Sci 2020; 15(2):85. <https://doi.org/10.1016/j.jtumed.2020.04.001>
4. Marwah A, Marwah P. Coronavirus (COVID-19): A protocol for prevention, treatment and control. J App Nat Sci 2020:119-123. <https://doi.org/10.31018/jans.vi.2269>
5. Nkeck JR, Tsafack EE, Ndoadoumgue AL, Endomba FT. An alert on the incautious use of herbal medicines by sub-Saharan African populations to fight against the COVID-19. The Pan African Med J 2020; 35(26). <https://doi.org/10.11604/pamj.suppl.2020.35.2.23161>
6. Szalkai I, Radnai A, Karacsony F, Körmendi-Racz J, Nyerges A, Hegyi G. Possibilities of pre-hospital intervention in the prevention and treatment of COVID-19 recommendations of The Hungarian Integrative Medicine Association. J Med Healthcare SRC/JMHC/118 J Med Healthcare 2020; 2(2):2.
7. Ainane T. Moroccan traditional treatment for fever and influenza, similar to symptoms of coronavirus COVID-19 disease: Mini Review. J Analyt Sci App Biotech 2020;2(1):1-3.
8. Chakraborty MK. Novel Corona Virus Disease 19 (N COVID-19) Epidemic origin, symptoms and precaution measure. Purakala 2020;31(8):1395-1409.
9. Panyod S, Ho C-T, Sheen L-Y. Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective. J Trad Comp Med 2020; 10(4):420-27. <https://doi.org/10.1016/j.jtcm.2020.05.004>
10. Lim GY. Essential oils and COVID-19: Industry warns no sufficient evidence for efficacy amid sales surge. 2020;
11. Ashley DD. Unapproved and Misbranded Products Related to Corona virus Disease 2019 (COVID-19). 2020;
12. Shelley A, Horner K. Otolaryngology: Nasal perforation. British Dent J 2017; 222(7):495-495. <https://doi.org/10.1038/sj.bdj.2017.288>
13. Sadlon AE, Lamson DW. Immune-modifying and antimicrobial effects of Eucalyptus oil and simple inhalation devices. Alt Med Rev 2010; 15(1):33-43.
14. Assessment report on Eucalytus globulus Labill., Eucalyptus polybractea R.T. Baker and/or *Eucalyptus smithii* R.T. Baker, aetheroleum.
15. Pasdaran A, Sheikhi D. Volatile oils: Potential agents for the treatment of respiratory infections. The Microbiology of Respiratory System Infections. Elsevier; 2016:237-261. <https://doi.org/10.1016/B978-0-12-804543-5.00016-6>
16. Sweetman S. The complete drug reference (Martindale). The Pharmaceutical Press, London; 2007.
17. FDA. OTC Active Ingredients.
18. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe corona virus disease 2019 (COVID-19). Respiratory Medicine. 2020; 167:105941. <https://doi.org/10.1016/j.rmed.2020.105941>
19. Wang L, Sun J, Li W, Lv Y, Shi W, Zhao C. Protective effect of eucalyptus oil against pulmonary destruction and inflammation in COPD rats. J Dis Med Plts 2017; 3:17-22. <https://doi.org/10.11648/j.jdmp.20170301.14>

20. Rantzsch U, Vacca G, Dück R, Gillissen A. Anti-inflammatory effects of Myrtle standardized and other essential oils on alveolar macrophages from patients with chronic obstructive pulmonary disease. *European J Med Res* 2009; 14(4):1-5.
<https://doi.org/10.1186/2047-783X-14-S4-205>
21. Cermelli C, Fabio A, Fabio G, Quaglio P. Effect of eucalyptus essential oil on respiratory bacteria and viruses. *Curr Micro* 2008; 56(1):89-92.
<https://doi.org/10.1007/s00284-007-9045-0>
22. Schnitzler P, Schön K, Reichling J. Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture. *Die Pharmazie* 2001; 56(4):343-347. PMID: 11338678
23. Vimalanathan S, Hudson J. Anti-influenza virus activity of essential oils and vapors. *American J Essent Oils Nat Prod* 2014;2(1):47-53.
24. Vail III WB, Vail ML. Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS). Google Patents; 2006.
25. Mulyaningsih S, Sporer F, Reichling J, Wink M. Antibacterial activity of essential oils from Eucalyptus and of selected components against multidrug-resistant bacterial pathogens. *Pharm Biol* 2011; 49(9):893-899.
<https://doi.org/10.3109/13880209.2011.553625>
26. Amini N, Rezaei K, Yazdannik A. Effect of nebulized eucalyptus on contamination of microbial plaque of endotracheal tube in ventilated patients. *Iranian J Nursing Midwifery Res* 2016; 21(2):165.
<https://doi.org/10.4103/1735-9066.178242>
27. Suman A, Chauhan S, Lata S, Sharma RK. Antifungal activity of various plant oils against yeast isolates from ICU patients. *Int J Res Med Sci* 2017; 5(7):3227.
<https://doi.org/10.18203/2320-6012.ijrms20173018>
28. Han X, Parker TL, Dorsett J. An essential oil blend significantly modulates immune responses and the cell cycle in human cell cultures. *Cogent Biol* 2017; 3(1):1340112.
<https://doi.org/10.1080/23312025.2017.1340112>
29. Serafino A, Vallebona PS, Andreola F, *et al.* Stimulatory effect of Eucalyptus essential oil on innate cell-mediated immune response. *BMC Immunol* 2008; 9(1):17.
<https://doi.org/10.1186/1471-2172-9-17>
30. Ingraham NE, Lotfi-Emran S, Thielen BK, *et al.* Immunomodulation in COVID-19. *The Lancet Respiratory Medicine* 2020;
[https://doi.org/10.1016/S2213-2600\(20\)30226-5](https://doi.org/10.1016/S2213-2600(20)30226-5)
31. Yadav N, Chandra H. Suppression of inflammatory and infection responses in lung macrophages by eucalyptus oil and its constituent 1, 8-cineole: Role of pattern recognition receptors TREM-1 and NLRP3, the MAP kinase regulator MKP-1, and NFκB. *PLoS One*. 2017; 12(11):e0188232.
<https://doi.org/10.1371/journal.pone.0188232>
32. Jun YS, Kang P, Min SS, Lee J-M, Kim H-K, Seol GH. Effect of eucalyptus oil inhalation on pain and inflammatory responses after total knee replacement: a randomized clinical trial. *Evidence-Based Com Alt Med* 2013. <https://doi.org/10.1155/2013/502727>
33. Penfold AR. Eucalyptus Oils. *Environment: a magazine of science*. 1934; 1(3).
34. Mandal S. Repellent activity of Eucalyptus and *Azadirachta indica* seed oil against the filarial mosquito *Culex quinquefasciatus* Say (Diptera: Culicidae) in India. *Asian Pac J Trop Biomed* 2011;1(1):S109-S112.
[https://doi.org/10.1016/S2221-1691\(11\)60135-4](https://doi.org/10.1016/S2221-1691(11)60135-4)
35. Kutumian DM. Multipurpose cleaner and method of cleaning using therapeutic grade essential oils. Google Patents; 2012.
36. Fugh-Berman A. The 5-minute herb and dietary supplement consult. Lippincott Williams and Wilkins; 2003. <https://doi.org/10.4065/78.11.1436-a>
37. Organization WH. WHO monographs on selected medicinal plants. Vol 2. World Health Organization; 1999.
38. Carson C, Riley T, Cookson B. Efficacy and safety of tea tree oil as a topical antimicrobial agent. *J Hospital Inf* 1998;40(3):175-178.
[https://doi.org/10.1016/S0195-6701\(98\)90135-9](https://doi.org/10.1016/S0195-6701(98)90135-9)
39. Shalaby SE, El-Din MM, Abo-Donia SA, Mettwally M, Attia ZA. Toxicological affects of essential oils from eucalyptus *Eucalyptus globules* and clove *Eugenia caryophyllus* on albino rats. *Pol J Environ Stud*. 2011; 20(2):429-434.
40. Mathew T, Kamath V, Kumar RS, *et al.* Eucalyptus oil inhalation-induced seizure: A novel, under recognized, preventable cause of acute symptomatic seizure. *Epilepsia Open* 2017;2(3):350-354.
<https://doi.org/10.1002/epi4.12065>
41. Niggemann B, Grüber C. Side effects of complementary and alternative medicine. *Allergy* 2003;58(8):707-716.
<https://doi.org/10.1034/j.1398-9995.2003.00219.x>
42. Devi MP, Chakrabarty S, Ghosh S, Bhowmick N. Essential oil: its economic aspect, extraction, importance, uses, hazards and quality. Value addition of horticultural crops: recent trends and future directions. Springer; 2015:269-278.
https://doi.org/10.1007/978-81-322-2262-0_15
43. Kehrl W, Sonnemann U, Dethlefsen U. Therapy for acute nonpurulent rhino sinusitis with cineole: results of a double blind, randomized, placebo controlled trial. *The Laryngoscope* 2004;114(4):738-742.
<https://doi.org/10.1097/00005537-200404000-00027>
44. Tesche S, Metternich F, Sonnemann U, Engelke J-C, Dethlefsen U. The value of herbal medicines in the treatment of acute non-purulent rhinosinusitis. *European Arch Oto-rhino-Laryngo* 2008; 265(11):1355.
<https://doi.org/10.1007/s00405-008-0683-z>